Cystic fibrosis drug developer Sionna rises on trading debut
Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharma focused on developing cystic fibrosis therapies, opened well above its initial public offering price on Friday in its first trading ...
BioSpace15h
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
South Boston Online16h
Important New VERTEX Painkiller Is Approved
By Rick Winterson  Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge.  It has now established its global headquarters on Fan Pier in South ...
FiercePharma18h
Looking ahead at the most anticipated drug launches of 2025
If Fierce Pharma Marketing’s annual list of the top 10 biggest potential drug launches of the coming year is any indication, ...
FierceBiotech22h
CF-focused Sionna goes public in $135M IPO, while Aardvark plots $103M listing
Cystic fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...